CN103211901A - Lung clearing and inflammation diminishing medicament and preparation method thereof - Google Patents
Lung clearing and inflammation diminishing medicament and preparation method thereof Download PDFInfo
- Publication number
- CN103211901A CN103211901A CN2013101137952A CN201310113795A CN103211901A CN 103211901 A CN103211901 A CN 103211901A CN 2013101137952 A CN2013101137952 A CN 2013101137952A CN 201310113795 A CN201310113795 A CN 201310113795A CN 103211901 A CN103211901 A CN 103211901A
- Authority
- CN
- China
- Prior art keywords
- sheet
- lung
- medicament
- rhizoma coptidis
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention aims to provide a lung clearing and inflammation diminishing medicament and a preparation method thereof. The medicament is characterized by consisting of the following components: 250 to 350 g of honeysuckle, 130 to 240 g of skullcap slices, 250 to 350 g of indigowoad leaf, 130 to 240 g of ephedra slices, 130 to 240 g of bitter apricot seeds, 130 to 240 g of houttuynia slices, 250 to 350 g of gypsum, 130 to 240 g of coptis, and 130 to 240 g of honey-fried licorice root slices. The medicament is an addition-reduction formula based on the empirical formula of Maxingshigan decoction applied to clinic for years. The medicament has the effects of clearing heat, freeing lung, relieving cough, reducing sputum and relieving asthma, and is mainly used for treating lung heat type cough and gasp syndromes.
Description
Technical field
The invention belongs to the field of Chinese medicines, a kind of lung-clearing anti-inflammatory medicine and preparation method thereof is provided especially.
Background technology
Pneumonia is by cause of disease classification, mainly contain infectious and physics and chemistry such as lonizing radiation, poison, medicine and allergy such as hypersensitivity pneumonitis etc., clinical findings is most to be the infectious pneumonia that antibacterial, virus, chlamydia, mycoplasma, rickettsia, fungus and parasite etc. cause, wherein common with antibacterial.
The pathogen of pneumonia has than big-difference because of host's age, accompanying diseases and immune functional state, acquisition mode (pneumonia in community acquired pneumonia or the hospital).The commonly encountered diseases substance of community acquired pneumonia is streptococcus pneumoniae, hemophilus influenza, staphylococcus aureus, micrococcus scarlatinae, legionella, anaerobe and virus, mycoplasma and chlamydia etc., and is then common with bacillus pyocyaneus and other pseudomonass, pneumobacillus, escherichia coli, cloaca and generation enterobacteria, Bacillus proteus, methicillin-resistant gold Portugal bacterium (mrsa) and fungus etc. in the pneumonia in the hospital.The aspiration pneumonitis great majority are anaerobic infection.
In the pneumonia that causes at mycoplasma, because mycoplasma does not have cell wall, to suppressing the synthetic medicine of cell wall, as penicillin, vancomycin, natural drug resistances such as cephalosporins, sulfonamides.Nearly ten years in the research at the mycoplasma pneumoniae resistance mechanism, especially obtained the third generation in the research at erythromycin and derivant structure transformation thereof to the effective macrolide antibiotics of fastbacteria, and find that mycoplasma pneumoniae may play a role to generation, the development of asthma, the relation of mycoplasma infection and asthma comes into one's own day by day.
The pathogenesis of mycoplasma pneumonia and immune factor have very big relation, and the acute lung injury of mycoplasma infection is relevant with the reaction of host's panimmunity, and mycoplasma pneumoniae infection is played a role in asthma in acute attack.Evidence show in the case that acute asthma increases the weight of, the mycoplasma pneumoniae infection rate up to 20% is arranged.Clinical evidence shows, to the child and the serious mycoplasma pneumonia of being grown up, adds with hormone on the antibiotic basis of use and can significantly improve disease course and prognosis, therefore to serious mycoplasma pneumonia, recommends to add to use hormone.
In the past for children Streptococcus with antiinflammatory, it is main standing up, clap the back of the body, inhaling the expectorant symptomatic treatment, often the long curative effect of the course of disease is not good enough.The branchofiberoscope treatment can be looked at straight down and be exhausted sputum, inject normal saline dilution and cleaning mucus bolt, to remove antibacterial and toxin, reduce and block and the bronchial mucosa congestion and edema, remove the inflammatory mediator and the reaction that reduces inflammation, improve respiratory symptom and ventilatory function, also can shorten the course of disease, prevent the generation of Resistant strain.But because the technical conditions of branchofiberoscope require highly, and expense is higher relatively, and risk is relatively large, also restricted its application in child's serious symptom mycoplasma pneumonia.
Present antibiotic abuse condition has caused the continuous enhancing of resistance, and Resistant strain is also more and more, and doctor trained in Western medicine does not more have effective Therapeutic Method for viral infection at present.The traditional Chinese medical science thinks that acute pneumonia belongs to the wind-warm lung-heat disease in the traditional Chinese medical science, mainly is because the lung that wind heat virus is caused becomes silted up.In the process of treatment primary disease, need to adopt " thoroughly " of the traditional Chinese medical science " to let out " method.Mycoplasma infection mainly shows as cough, and main pathogenesis is impaired depurative descending of lung QI or turbid phlegm obstructing in the lung, and Lung Qi obstraction forms, and the Therapeutic Principle should be based on the dispersing lung-QI and dissipating phlegm cough-relieving.
Summary of the invention
The object of the present invention is to provide a kind of lung-clearing anti-inflammatory medicine and preparation method thereof, this medicine is to be used for the clinical plus-minus side on proved recipe MAXINGSHIGAN TANG basis for many years.This side has reducing heat and dispersing lung-QI, relieving cough and resolving phlegm, the effect of assistant to relieving asthma.Be mainly used in the treatment lung-heat and stop up pulmonary type cough, the syndrome of dyspnea.Through the clinical practice decades good clinical curative effect is arranged.
The present invention specifically provides a kind of lung-clearing anti-inflammatory medicine, it is characterized in that, the composition of described medicine and the ratio of each component is: Flos Lonicerae 250～350g, scutellaria tablet 130～240g, Folium Isatidis 250～350g, Herba Ephedrae sheet 130～240g, Semen Armeniacae Amarum 130～240g, Herba Houttuyniae sheet 130～240g, Gypsum Fibrosum 250～350g, Rhizoma Coptidis 130～240g, Radix Glycyrrhizae Preparata sheet 130～240g.
The present invention also provides the best prescription of this medicine, it is characterized in that, the ratio of each component is: Flos Lonicerae 310g, scutellaria tablet 185g, Folium Isatidis 310g, Herba Ephedrae sheet 185g, Semen Armeniacae Amarum 185g, Herba Houttuyniae sheet 185g, Gypsum Fibrosum 310g, Rhizoma Coptidis 185g, Radix Glycyrrhizae Preparata sheet 185g.
The invention provides the preparation method of described lung-clearing anti-inflammatory medicine, it is characterized in that: Rhizoma Coptidis adds 12 times of water gagings, soaks 2 hours, extracted 2 hours, and filtered, medicinal residues add 10 times of water gagings again, extracted 1 hour, filter, merge filtrate twice, put standing over night in the settling tank, it is 1.10～1.40 thick paste that supernatant is evaporated to relative density at 60 ℃, to doing, be ground into fine powder in 85 ℃ of drying under reduced pressure, standby; Get all the other eight flavor medicines and add 10 times of water gagings, extracted 2 hours, filter; medicinal residues add 10 times of water gagings again; extracted 1 hour, and filtered, merge filtrate twice; put standing over night in the settling tank; it is 1.10～1.40 clear paste thick paste that supernatant is evaporated to relative density at 60 ℃, to doing, is ground into fine powder in 70 ℃ of drying under reduced pressure; with Rhizoma Coptidis water extraction fine powder mixing, granulation or compacting are in flakes.
That the lightly seasoned little hardship of Flos Lonicerae in the medicine of the present invention, heat-clearing and toxic substances removing, dispelling wind and heat pathogens, water extract and liposoluble ingredient have is antibacterial, antiinflammatory, antiviral, effects such as heat-clearing and toxic substances removing; The Radix Scutellariae bitter in the mouth, cold, return lung, gallbladder, spleen, large intestine, small intestine meridian, decocting liquid has antiinflammatory, antiviral effect, and the skullcapflavone constituents has the effect of antiinflammatory, antiviral, heat-clearing and toxic substances removing; Folium Isatidis property hardship, cold, GUIXIN, stomach warp have the effect of antibacterial, antiinflammatory, antiviral, heat-clearing and toxic substances removing; The Herba Houttuyniae suffering is slightly cold, and returns lung meridian, has antiinflammatory, antibacterial, antiviral, effect that liter is white, and Herba Houttuyniae volatile oil has anti-antiviral, cough-relieving, antitussive, analgesia, antipyretic effect, the Quercetin in the Herba Houttuyniae have eliminate the phlegm, effect such as cough-relieving; Herba Ephedrae acrid in the mouth, little hardship, temperature is returned lung, urinary bladder channel, and Herba Ephedrae alkaloid can excited respiratory center cause bronchiectasis, and the diastole bronchial smooth muscle has antiphlogistic effect; Herba Ephedrae volatile oil have relieving asthma, cough-relieving, eliminate the phlegm, antiallergic and bacteriostasis; Flavones ingredient has the DPPH of removing freedom in the Herba Ephedrae, suppresses the effect of A/PR/8 virus.Ephedran has the effect of the free radical of removing; The Semen Armeniacae Amarum bitter in the mouth, tepor, slightly poisonous, return lung, large intestine channel, amygdaloside is a Chinese medicine Semen Armeniacae Amarum effective ingredient, and the micro-hydrocyanic acid of its hydrolysis can play the effect effect of antitussive and antiasthmatic, amygdaloside can suppress the adjuvanticity inflammation, strengthen the phagocytic function of macrophage, have the effect of regulating immunologic function, the Semen Armeniacae Amarum polysaccharide also has very strong scavenging action to ultra-oxygen anion free radical; Gypsum Fibrosum has and suppresses the hyperfunction of thermotaxic centre and produce strong refrigeration function, and sweat centers also is suppressed simultaneously, thus analgesic and not diaphoresis, the fraud effect of no impairment of body fluid; Effects such as that Rhizoma Coptidis has is antibiotic, antiendotoxin, antiviral, enhance immunity, heat clearing away, detoxifcation, dampness, antiulcer, blood sugar lowering, main antipathogenic composition is a berberine; The Radix Glycyrrhizae sweet in the mouth, flat, GUIXIN, lung, spleen, stomach warp have Detoxication, and glycyrrhizic acid, enoxolone have detoxifcation, antiinflammatory, antitussive, antitumor, antiulcer, effect such as antibiotic.More than all medicines, be that compatibility is proper, prescription is rigorous, treating both the principal and secondary aspects of a disease is to reach the purport of reducing heat and dispersing lung-QI, relieving cough and resolving phlegm.
Experimentatioies such as clinical efficacy that medicine of the present invention early stage is comparatively satisfied and pharmacology, toxicology have all further proved the clinical efficacy and the safety of this medicine, finally make to be fit to the patient and to take determined curative effect, Chinese medicine preparation safely and effectively.
The specific embodiment
Pharmaceutical preparation: Rhizoma Coptidis adds 12 times of water gagings, soaks 2 hours, extracts 2 hours, filter, medicinal residues add 10 times of water gagings again, extract 1 hour, filter, merge filtrate twice, put standing over night in the settling tank, it is 1.30 thick paste that supernatant is evaporated to relative density at 60 ℃, in 85 ℃ of drying under reduced pressure to doing, be ground into fine powder, standby; Get all the other eight flavor medicines and add 10 times of water gagings, extracted 2 hours, filter; medicinal residues add 10 times of water gagings again; extracted 1 hour, and filtered, merge filtrate twice; put standing over night in the settling tank; it is 1.30 clear paste thick paste that supernatant is evaporated to relative density at 60 ℃, to doing, is ground into fine powder in 70 ℃ of drying under reduced pressure; with Rhizoma Coptidis water extraction fine powder mixing, granulation or compacting are in flakes.
Embodiment 1
Medicine material comprises: Flos Lonicerae 310g, scutellaria tablet 185g, Folium Isatidis 310g, Herba Ephedrae sheet 185g, Semen Armeniacae Amarum 185g, Herba Houttuyniae sheet 185g, Gypsum Fibrosum 310g, Rhizoma Coptidis 185g, Radix Glycyrrhizae Preparata sheet 185g.
Xylol causes the influence of mice auricular concha swelling
Get 60 of the healthy male km mices of body weight 18～22g, divide 6 groups at random by body weight, every group 10, be respectively model control group, this product low dose group 2.5g/kg, middle dosage group 5.0g/kg, high dose group 10.0g/kg, Chinese medicine positive control drug lung-clearing anti-inflammatory ball group 6.24g/kg and Western medicine positive control drug dexamethasone acetate group 1.56mg/kg.Each treated animal is irritated stomach by corresponding dosage and is given corresponding medicinal liquid, and model control group is irritated stomach and given the equivalent distilled water, and the administration volume is 20ml/kg, successive administration 7d.After the last administration 30 minutes, 20 μ l dimethylbenzene are applied to the mouse right ear exterior feature, stopped for 15 seconds, put to death animal after 20 minutes, cut two ears, get the auricle of two ear same area with the 8mm card punch, analytical balance is weighed, as the swelling degree, the ear swelling degree significance of difference between each administration group and the model control group is compared in the t check with two auricle weight differences.The results are shown in Table 1.
Table 1 xylol causes the influence of mice auricular concha swelling
Compare with model control group,
*P＜0.05,
* *P＜0.01
By table 1 result of the test as seen, basic, normal, high three the dosage groups of this product, lung-clearing anti-inflammatory ball group and dexamethasone acetate group all can obviously reduce the mice ear degree that dimethylbenzene causes, with model control group significant difference (P＜0.05 is arranged more all, P＜0.01), shows that this product extract has antiinflammatory action.
The mice strong aqua ammonia is lured the influence of coughing
Get 60 of the healthy km mices of body weight 18～22g, be divided into 6 groups at random by the sex body weight, every group 10, each 5 of male and female, be respectively model control group, this product low dose group 2.5g/kg, middle dosage group 5.0g/kg, high dose group 10.0g/kg, Chinese medicine positive control drug lung-clearing anti-inflammatory ball group 6.24g/kg and Western medicine positive control drug Ao Buke group 20.8mg/kg.Each treated animal is irritated stomach by corresponding dosage and is given corresponding medicinal liquid, and model control group is irritated stomach and given the equivalent distilled water, and the administration volume is 20ml/kg, successive administration 7d.After the last administration 30 minutes, mice put into be added with luring of strong aqua ammonia and cough to draw and breathe heavily instrument, atomized for 5 seconds, the cough latent period of observed and recorded mice and the number of times of coughing in 2 minutes, the cough latent period and the cough number of times significance of difference between each administration group and the model control group are compared in the t check, and experimental result sees Table 2.
The antitussive action of table 2 extract
Compare with model control group,
*P＜0.05,
*P＜0.01
By table 2 result of the test as seen, basic, normal, high three the dosage groups of this product, lung-clearing anti-inflammatory ball group and Ao Buke group all can obviously prolong the mouse cough incubation period that ammonia causes, reduce mouse cough number of times in the 2min, with model control group difference (P＜0.05 of highly significant is arranged more all, P＜0.01), shows that this product has antitussive action.
Embodiment 2
Medicine material comprises: Flos Lonicerae 250g, scutellaria tablet 130g, Folium Isatidis 250g, Herba Ephedrae sheet 185g, Semen Armeniacae Amarum 185g, Herba Houttuyniae sheet 130g, Gypsum Fibrosum 310g, Rhizoma Coptidis 130g, Radix Glycyrrhizae Preparata sheet 185g.
Table 3 xylol causes the influence of mice auricular concha swelling
By table 3 result as can be known, this prescription xylol causes the swelling of mice auricular concha inhibitory action, and wherein the inhibitory action of high dose group is similar in the Chinese medicine matched group.
The antitussive action of table 4 extract
By table 4 result as can be known, this prescription can effectively prolong cough latent period, and reduces cough number of times in the 2min.High dose group can reach the antitussive action identical with the Chinese medicine matched group.
Embodiment 3
Medicine material comprises: Flos Lonicerae 350g, scutellaria tablet 240g, Folium Isatidis 350g, Herba Ephedrae sheet 185g, Semen Armeniacae Amarum 185g, Herba Houttuyniae sheet 240g, Gypsum Fibrosum 310g, Rhizoma Coptidis 240g, Radix Glycyrrhizae Preparata sheet 185g.
Table 5 xylol causes the influence of mice auricular concha swelling
By table 5 result as can be known, this prescription xylol causes the swelling of mice auricular concha inhibitory action, and wherein except that low dose group, other dosage group inhibitory action and Chinese medicine matched group are similar.
The antitussive action of table 6 extract
By table 6 result as can be known, this prescription can effectively prolong cough latent period, and reduces cough number of times in the 2min.Middle dosage group can reach the antitussive action identical with the Chinese medicine matched group.
Embodiment 4
Medicine material comprises: Flos Lonicerae 310g, scutellaria tablet 185g, Folium Isatidis 310g, Herba Ephedrae sheet 130g, Semen Armeniacae Amarum 130g, Herba Houttuyniae sheet 185g, Gypsum Fibrosum 250g, Rhizoma Coptidis 185g, Radix Glycyrrhizae Preparata sheet 130g.
Table 7 xylol causes the influence of mice auricular concha swelling
By table 7 result as can be known, this each dosage group xylol of writing out a prescription causes the swelling of mice auricular concha has inhibitory action and Chinese medicine matched group similar.
The antitussive action of table 8 extract
By table 8 result as can be known, this prescription can effectively prolong cough latent period, and reduces cough number of times in the 2min.Middle dosage group can reach the antitussive action identical with the Chinese medicine matched group.
Embodiment 5
Medicine material comprises: Flos Lonicerae 310g, scutellaria tablet 185g, Folium Isatidis 310g, Herba Ephedrae sheet 240g, Semen Armeniacae Amarum 240g, Herba Houttuyniae sheet 185g, Gypsum Fibrosum 320g, Rhizoma Coptidis 185g, Radix Glycyrrhizae Preparata sheet 240g.
Table 9 xylol causes the influence of mice auricular concha swelling
By table 9 result as can be known, this prescription high dose group xylol causes the swelling of mice auricular concha has inhibitory action and Chinese medicine matched group similar.
The antitussive action of table 10 extract
By table 10 result as can be known, this prescription can effectively prolong cough latent period, and reduces cough number of times in the 2min.Middle dosage group can reach the antitussive action identical with the Chinese medicine matched group.
More than the test method of all embodiment all identical with example 1, all tests all meet "
*P＜0.05,
*P＜0.01 ".
The foregoing description only is explanation technical conceive of the present invention and characteristics, and its purpose is to allow the personage who is familiar with this technology can understand content of the present invention and enforcement according to this, can not limit protection scope of the present invention with this.All equivalences that spirit is done according to the present invention change or modify, and all should be encompassed within protection scope of the present invention.
Claims (3)
1. lung-clearing anti-inflammatory medicine, it is characterized in that, the composition of described medicine and the ratio of each component is: Flos Lonicerae 250～350g, scutellaria tablet 130～240g, Folium Isatidis 250～350g, Herba Ephedrae sheet 130～240g, Semen Armeniacae Amarum 130～240g, Herba Houttuyniae sheet 130～240g, Gypsum Fibrosum 250～350g, Rhizoma Coptidis 130～240g, Radix Glycyrrhizae Preparata sheet 130～240g.
2. according to the described lung-clearing anti-inflammatory medicine of claim 1, it is characterized in that described the ratio of each component is: Flos Lonicerae 310g, scutellaria tablet 185g, Folium Isatidis 310g, Herba Ephedrae sheet 185g, Semen Armeniacae Amarum 185g, Herba Houttuyniae sheet 185g, Gypsum Fibrosum 310g, Rhizoma Coptidis 185g, Radix Glycyrrhizae Preparata sheet 185g.
3. the preparation method of the described lung-clearing anti-inflammatory medicine of claim 1, it is characterized in that: Rhizoma Coptidis adds 12 times of water gagings, soaks 2 hours, extracted 2 hours, and filtered, medicinal residues add 10 times of water gagings again, extracted 1 hour, filter, merge filtrate twice, put standing over night in the settling tank, it is 1.10～1.40 thick paste that supernatant is evaporated to relative density at 60 ℃, to doing, be ground into fine powder in 85 ℃ of drying under reduced pressure, standby; Get all the other eight flavor medicines and add 10 times of water gagings, extracted 2 hours, filter; medicinal residues add 10 times of water gagings again; extracted 1 hour, and filtered, merge filtrate twice; put standing over night in the settling tank; it is 1.10～1.40 clear paste thick paste that supernatant is evaporated to relative density at 60 ℃, to doing, is ground into fine powder in 70 ℃ of drying under reduced pressure; with Rhizoma Coptidis water extraction fine powder mixing, granulation or compacting are in flakes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310113795.2A CN103211901B (en) | 2013-04-02 | 2013-04-02 | Lung clearing and inflammation diminishing medicament and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310113795.2A CN103211901B (en) | 2013-04-02 | 2013-04-02 | Lung clearing and inflammation diminishing medicament and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103211901A true CN103211901A (en) | 2013-07-24 |
| CN103211901B CN103211901B (en) | 2015-02-04 |
Family
ID=48810287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310113795.2A Expired - Fee Related CN103211901B (en) | 2013-04-02 | 2013-04-02 | Lung clearing and inflammation diminishing medicament and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103211901B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103505530A (en) * | 2013-07-30 | 2014-01-15 | 黄淮学院 | Traditional Chinese medicine composition for treating variability measles |
| CN103656601A (en) * | 2013-12-23 | 2014-03-26 | 青岛安信医疗器械有限公司 | Traditional Chinese medicinal decoction for treating bacterial pneumonia |
| CN104623047A (en) * | 2015-02-13 | 2015-05-20 | 安徽恒源药业有限公司 | Traditional Chinese medicine preparation for treating respiratory tract diseases of livestock |
| CN104758433A (en) * | 2015-03-17 | 2015-07-08 | 梁晓 | Traditional Chinese medicine composition for treating chronic bronchitis in the type of external cold and internal heat |
| CN105250471A (en) * | 2015-11-04 | 2016-01-20 | 安徽益健堂中药饮片科技有限公司 | Traditional Chinese medicine composition for treating pneumonia |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1097320A (en) * | 1993-07-13 | 1995-01-18 | 四川省中药厂 | Sugarless type infantile lung heat instant powder for asthma and cough and preparation method thereof |
| CN1733110A (en) * | 2005-08-12 | 2006-02-15 | 山东鲁泰环中制药有限公司 | Chinese medicinal composition for clearing heat, dispersing phlegm, ventilating the lung and relieving asthma and process for preparing the same |
| CN102357154A (en) * | 2011-11-01 | 2012-02-22 | 天津生机集团股份有限公司 | Traditional Chinese medicine composition for preventing and treating avian infectious bronchitis and preparation method thereof |
| CN102716317A (en) * | 2012-06-18 | 2012-10-10 | 天津开发区经经新优技术产品开发有限公司 | Chinese patent medicine and TCM decoction capable of effectively curing lobar pneumonia |
-
2013
- 2013-04-02 CN CN201310113795.2A patent/CN103211901B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1097320A (en) * | 1993-07-13 | 1995-01-18 | 四川省中药厂 | Sugarless type infantile lung heat instant powder for asthma and cough and preparation method thereof |
| CN1733110A (en) * | 2005-08-12 | 2006-02-15 | 山东鲁泰环中制药有限公司 | Chinese medicinal composition for clearing heat, dispersing phlegm, ventilating the lung and relieving asthma and process for preparing the same |
| CN102357154A (en) * | 2011-11-01 | 2012-02-22 | 天津生机集团股份有限公司 | Traditional Chinese medicine composition for preventing and treating avian infectious bronchitis and preparation method thereof |
| CN102716317A (en) * | 2012-06-18 | 2012-10-10 | 天津开发区经经新优技术产品开发有限公司 | Chinese patent medicine and TCM decoction capable of effectively curing lobar pneumonia |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103505530A (en) * | 2013-07-30 | 2014-01-15 | 黄淮学院 | Traditional Chinese medicine composition for treating variability measles |
| CN103505530B (en) * | 2013-07-30 | 2015-05-13 | 黄淮学院 | Traditional Chinese medicine composition for treating variability measles |
| CN103656601A (en) * | 2013-12-23 | 2014-03-26 | 青岛安信医疗器械有限公司 | Traditional Chinese medicinal decoction for treating bacterial pneumonia |
| CN104623047A (en) * | 2015-02-13 | 2015-05-20 | 安徽恒源药业有限公司 | Traditional Chinese medicine preparation for treating respiratory tract diseases of livestock |
| CN104758433A (en) * | 2015-03-17 | 2015-07-08 | 梁晓 | Traditional Chinese medicine composition for treating chronic bronchitis in the type of external cold and internal heat |
| CN105250471A (en) * | 2015-11-04 | 2016-01-20 | 安徽益健堂中药饮片科技有限公司 | Traditional Chinese medicine composition for treating pneumonia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103211901B (en) | 2015-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101708275B (en) | Chinese medicament for treating flu caused by influenza A(H1N1) and the like | |
| CN101700307B (en) | Traditional Chinese medicine for curing chronic pharyngolaryngitis | |
| CN102813801B (en) | Traditional Tibetan medicine for treating cough and preparation method thereof | |
| CN103212006A (en) | Traditional Chinese medicine for treating chronic bronchitis | |
| CN103211901B (en) | Lung clearing and inflammation diminishing medicament and preparation method thereof | |
| CN100512850C (en) | Lung heat-cleaning throat-moistening cough-relieving syrup | |
| CN104107216A (en) | Traditional Chinese medicine compound preparation and its preparation method and use | |
| CN101596272A (en) | A kind of medicine for the treatment of chronic pharyngitis and preparation method thereof | |
| CN104800597A (en) | Traditional Chinese medicine composition for treating sphagitis | |
| CN104983968B (en) | Antipyretic traditional Chinese medicine composition and preparation method thereof | |
| CN102784380A (en) | Traditional Chinese medicine preparation for treating pertussis | |
| CN103330767B (en) | Tibetan medicine for curing cough and preparing method thereof | |
| CN102526236B (en) | Pharmaceutical formulation for treating influenza and preparation method thereof | |
| CN1150927C (en) | Stomatopathy and throat disease treating health care medicine and its production process | |
| CN102949516A (en) | Health-care product lozenge for pharyngitis and preparation method thereof | |
| CN106620205A (en) | Externally-used traditional Chinese medicine for foot bath to treat pediatric fever | |
| CN105327182A (en) | Medicine for treating child pertussis and preparation method thereof | |
| CN105879000A (en) | Pharmaceutic preparation for treating tonsillitis and application thereof | |
| CN104258020A (en) | Traditional Chinese medicine composition for treating pneumonia | |
| CN105343503B (en) | A kind of pharmaceutical composition that treating sphagitis and its application | |
| CN104524256A (en) | Traditional Chinese medicine for treating viral pneumonia | |
| CN103623203B (en) | A kind of preparation method of dimethoxanate oral formulations | |
| CN103566029B (en) | Pharmaceutical composition for treating respiratory diseases and preparation method and usage thereof | |
| CN102755524B (en) | Traditional Chinese medicine for treating chronic pharyngitis | |
| CN105362548A (en) | Traditional Chinese medicine for treating allergic asthma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150204 Termination date: 20170402 |